Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.52 Insider Own24.63% Shs Outstand52.56M Perf Week25.69%
Market Cap190.27M Forward P/E- EPS next Y-1.09 Insider Trans0.19% Shs Float39.62M Perf Month22.71%
Income-61.76M PEG- EPS next Q-0.32 Inst Own59.65% Short Float / Ratio0.67% / 0.64 Perf Quarter3.72%
Sales1.42M P/S133.99 EPS this Y28.51% Inst Trans-0.23% Short Interest0.27M Perf Half Y29.29%
Book/sh1.70 P/B2.13 EPS next Y16.94% ROA-51.46% Target Price11.75 Perf Year3.13%
Cash/sh1.95 P/C1.86 EPS next 5Y-1.60% ROE-69.60% 52W Range1.86 - 5.25 Perf YTD15.29%
Dividend- P/FCF- EPS past 5Y-40.24% ROI-69.29% 52W High-31.05% Beta-0.02
Dividend %- Quick Ratio5.45 Sales past 5Y69.56% Gross Margin15.25% 52W Low94.62% ATR0.32
Employees58 Current Ratio5.45 Sales Q/Q51.53% Oper. Margin-4419.54% RSI (14)62.53 Volatility10.14% 10.17%
OptionableYes Debt/Eq0.07 EPS Q/Q31.47% Profit Margin-4340.06% Rel Volume0.39 Prev Close3.31
ShortableYes LT Debt/Eq0.06 EarningsNov 07 AMC Payout- Avg Volume413.32K Price3.62
Recom1.00 SMA2019.18% SMA507.73% SMA20018.94% Volume162,563 Change9.37%
Date Action Analyst Rating Change Price Target Change
Oct-06-23Resumed BTIG Research Buy $15
Aug-31-23Initiated H.C. Wainwright Buy $12
May-24-22Initiated Cantor Fitzgerald Overweight $15
May-26-20Initiated William Blair Outperform
May-26-20Initiated Jefferies Buy $24
May-26-20Initiated BTIG Research Buy $28
May-26-20Initiated BofA/Merrill Buy $21
Nov-07-23 04:01PM
Oct-16-23 07:00AM
Sep-13-23 01:22PM
Sep-12-23 07:00AM
08:00AM Loading…
Sep-06-23 08:00AM
Aug-29-23 07:00AM
Aug-08-23 05:50PM
Jul-13-23 07:30AM
Jun-02-23 04:01PM
Jun-01-23 07:29AM
May-26-23 07:57AM
May-14-23 08:19AM
08:15AM Loading…
May-12-23 08:15AM
May-09-23 04:01PM
Apr-29-23 08:19AM
Apr-25-23 07:59AM
Mar-29-23 04:06PM
Mar-20-23 01:11PM
Mar-01-23 05:21AM
Feb-28-23 05:17AM
Feb-27-23 07:59AM
Feb-07-23 01:23PM
Feb-06-23 07:56AM
Jan-17-23 06:42PM
Dec-20-22 08:52AM
Nov-09-22 08:00AM
05:45PM Loading…
Nov-08-22 05:45PM
Sep-21-22 06:11AM
Sep-13-22 04:01PM
Sep-10-22 08:00AM
Sep-08-22 07:00AM
Sep-06-22 07:00AM
Aug-31-22 02:08PM
Aug-29-22 07:00AM
Aug-11-22 08:05AM
Aug-09-22 08:25AM
Jul-27-22 09:40AM
Jul-13-22 09:21AM
Jul-05-22 07:00AM
Jun-17-22 04:01PM
May-26-22 07:00AM
May-25-22 01:07PM
May-10-22 08:35AM
May-05-22 07:00AM
Apr-29-22 09:07AM
Apr-27-22 06:31AM
Apr-25-22 07:00AM
Apr-21-22 07:00AM
Apr-13-22 07:00AM
Apr-08-22 07:34AM
Mar-09-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 04:28AM
Feb-28-22 07:00AM
Feb-17-22 07:00AM
Jan-24-22 12:37PM
Nov-11-21 07:00AM
Nov-09-21 04:05PM
Nov-02-21 07:00AM
Oct-04-21 07:00AM
Sep-29-21 02:58PM
Sep-21-21 07:00AM
Sep-20-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 04:05PM
Sep-07-21 07:00AM
Sep-03-21 10:24AM
Aug-17-21 07:35AM
Aug-09-21 04:05PM
Aug-03-21 09:01AM
Jul-26-21 04:05PM
Jul-12-21 07:00AM
Jun-30-21 07:00AM
Jun-23-21 03:23PM
Jun-09-21 05:48AM
Jun-08-21 04:30PM
Jun-02-21 07:00AM
Jun-01-21 07:00AM
May-24-21 07:00AM
May-11-21 04:05PM
May-06-21 04:05PM
May-03-21 06:08AM
Apr-27-21 08:39AM
Mar-29-21 04:05PM
Mar-09-21 04:05PM
Mar-04-21 11:43AM
Mar-02-21 04:05PM
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waksal HarlanExecutive ChairNov 10Buy2.9625,00074,095261,966Nov 13 05:29 PM
PERCEPTIVE ADVISORS LLCDirectorMay 31Buy2.493,610,8328,999,99911,469,117Jun 02 04:11 PM
NBVM GP, LLC10% OwnerMay 31Buy2.431,805,4164,387,1612,521,745Jun 02 04:15 PM
ANDERSON EDWARD TDirectorMay 31Buy2.431,805,4164,387,1612,521,745Jun 02 04:11 PM